This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Henry Schein (HSIC) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of -2.42% and 1.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Henry Schein (HSIC)
by Zacks Equity Research
Henry Schein (HSIC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Becton Dickinson (BDX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 4% and 3.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed the most recent trading day at $80.01, moving -0.58% from the previous trading session.
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is a Beat Likely for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2023 results are expected to reflect solid performance in the Pharmaceutical segment. However, inflationary pressure is likely to have continued.
Embecta (EMBC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Charles River (CRL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued global demand for research models and associated services are likely to have driven Charles River's (CRL) Q1 revenues.
Alcon (ALC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Amid persistent supply-chain headwinds, Alcon's (ALC) first-quarter top-line results are likely to reflect the commercial execution of new product launches across its segments and contributions from strategic alliances.
What's in Store for DENTSPLY SIRONA (XRAY) in Q1 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) first-quarter 2023 results are likely to reflect strong performance in the Technologies & Equipment business.
AMN Healthcare (AMN) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AMN Healthcare's (AMN) first-quarter results are likely to reflect soft demand across its segments.
Henry Schein (HSIC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed at $81.19 in the latest trading session, marking a -0.02% move from the prior day.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) base business registers growth in the first quarter of 2023.
Integra's (IART) Q1 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
Edwards Lifesciences (EW) Q1 Earnings Top Estimates, '23 View Up
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL Precision system in Europe.
Lamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Lamb Weston and TTEC Holdings have been highlighted as Zacks Bull and Bear of the Day.
Align Technology (ALGN) Q1 Earnings Beat, Margins Contract
by Zacks Equity Research
Align Technology (ALGN) delivers better-than-expected revenues and earnings in the first quarter of 2023 but suffers significant foreign currency woes.
The Zacks Analyst Blog Highlights BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp
by Zacks Equity Research
BioRad Laboratories, Henry Schein, Insulet, Abbott and LabCorp are included in this Analyst Blog.
Zacks Industry Outlook Highlights West Pharmaceutical Services, The Cooper Companies and Henry Schein
by Zacks Equity Research
West Pharmaceutical Services, The Cooper Companies and Henry Schein have been highlighted in this Industry Outlook article.
CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q1.
Boston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised
by Zacks Equity Research
Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The year-over-year growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments drove Thermo Fisher's (TMO) Q1 revenues.
AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal 2023 second-quarter results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
3 Dental Supplies Stocks to Buy as Industry Prospects Recover
by Zacks Equity Research
Here, we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, COO and HSIC.
Illumina (ILMN) Q1 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.